BioCentury
ARTICLE | Financial News

Santhera raises $14.8 million selling treasury shares

August 16, 2014 1:13 AM UTC

Santhera Pharmaceuticals Holding AG (SIX:SANN) raised CHF13.4 million ($14.8 million) through the sale of 200,000 treasury shares at an average price of CHF 66.85. The company said the shares were sold over the past month.

Santhera's Raxone idebenone, a short-chain benzoquinone, is under review in the EU to treat Leber's hereditary optic neuropathy (LHON), with a decision expected in 1H15. The company withdrew a its MAA in 2013 but resubmitted earlier this year with additional clinical and natural history data (see BioCentury Extra, June 5). ...